Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Introduction to Antifungal Drugs

Dismukes, W. E.·2000·Clinical Infectious Diseases

Abstract

In the United States, only 10 antifungal drugs are currently approved by the Food and Drug Administration (FDA) for the therapy of systemic fungal infections. As shown in table 1, these drugs belong to 3 principal classes: polyenes, pyrimidines, and azoles. Drugs that belong to other classes are also approved as topical antifungal drugs, but will not be considered further here. Although conventional amphotericin B (Fungizone) remains the standard therapy for many invasive or life-threatening mycoses, this polyene drug is associated with significant toxicity, including infusion-related events, such as chills, fever, headache, nausea and vomiting, and dose-limiting nephrotoxicity [1]. In addition, the clinical efficacy of amphotericin B in some settings (e.g., mold disease such as invasive aspergillosis in severely immunocompromised patients) is suboptimal. Consequently, 3 new lipid formulations of amphotericin B (amphotericin B lipid complex, amphotericin B cholesteryl sulfate, and liposomal amphotericin B) have been developed and recently approved by the FDA. These lipid formulations offer several advantages over conventional amphotericin B, including increased daily dose of the parent drug (up to 10-fold), high tissue concentrations in the primary reticuloendothelial organs (lungs, liver, and spleen), decrease in infusion-associated side effects (especially liposomal amphotericin B), and marked decrease in nephrotoxicity [2‐3]. Although the therapeutic : toxic ratio of these compounds is clearly improved, superiority in clinical efficacy has not been definitively established in headto-head comparative trials, either a lipid formulation versus conventional amphotericin B or 1 lipid formulation versus another lipid formulation [4‐11]. Moreover, these lipid formulations of amphotericin B are considerably more expensive than conventional amphotericin B, ranging from 10- to 20-fold higher in cost per dose [3]. In addition, the optimum daily or total dose of these lipid compounds has not been established. Accordingly, unanswered questions and controversy abound about several issues relating to these 3 lipid agents [11]. For example, is 1 drug superior by pharmacologic and efficacy pa

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/313748

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 262

Metadata

Authors
Dismukes, W. E.
Venue
Clinical Infectious Diseases
Published
2000-04-01
Volume
30
Issue
4
Pages
653-657
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2139598390
Cited by
262
References
26
FWCI
11.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Introduction to Antifungal Drugs. https://app.cochat.ai/papers/10.1086/313748
The paper
Dismukes, W. E. (2000). Introduction to Antifungal Drugs. Clinical Infectious Diseases. https://doi.org/10.1086/313748

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.